Experimental Drug Daraxonrasib Eliminates Tumors in 8% of Advanced Pancreatic Cáncer Patients in Phase I/II Trial
An experimental oral medication, daraxonrasib, eliminated tumors in 8% of advanced pancreatic cancer patients during a phase I/II clinical trial.
An experimental oral medication, daraxonrasib, has shown encouraging results in reducing or eliminating tumors in patients with advanced pancreatic cancer during a phase I/II clinical trial.
- In a study of 61 participants, 90% of patients achieved stabilization or reduction of tumor growth.
- The treatment, which targets the KRAS mutation, resulted in complete, radiographically undetectable tumor disappearance in approximately 8% of subjects.
- Researchers caution that these findings are preliminary and do not yet constitute a confirmed cure for the disease.
Clinical Trial Results in Barcelona
The findings from the RMC-GI-102 trial were presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, according to Eldebate. Data collected through September 28, 2026, from 61 patients indicated that the combination of daraxonrasib and standard chemotherapy achieved a median progression-free survival of 12.8 months, according to El Debate. This duration exceeds historical outcomes for conventional chemotherapy, which typically range between 8.5 and 11.1 months for metastatic cases.
During a median follow-up period of 18.3 months, 60.7% of patients demonstrated an objective response to the therapy. Specifically, 52.5% experienced tumor reduction, while 8.2% achieved a complete response, defined as the disappearance of lesions on imaging scans, as reported by El Debate. Overall, 90.2% of the study group successfully halted tumor progression.
In the United Kingdom, pancreatic cancer registers about 11,500 new detections per year and causes around 10,200 deaths annually, according to Cancer Research UK data. In the United States, it accounts for 3% of all cancers and is responsible for 8% of cancer deaths, with approximately 53,000 fatalities per year. 76.6% of participants were alive one year after starting treatment.
Targeting the RAS Mutation
Pancreatic cancer frequently involves alterations in the RAS gene, which governs cellular growth. When mutated, this gene remains in an “ON” state, driving unchecked tumor proliferation. Daraxonrasib is designed to bind to the RAS protein in this active state, effectively blocking the signals that the cancer requires to survive and multiply.

“We are beginning to see not only a higher percentage of tumor response rates, but also deeper responses and nearly double the duration of disease control,” said Wungki Park, a gastrointestinal oncologist at the Memorial Sloan Kettering Cancer Center, who presented the findings, as reported by Infobae. Park said that in cases of significant response, the patient’s disease becomes invisible on standard scans.
“This is the closest thing to a cure,” Park said. He elaborated: “The median follow-up is 18 months. Imagine that in an average of 18 months your disease simply disappears on the scan… that is the closest thing to a complete remission… it is incredible.”
“What this new drug has achieved is finding a way to treat the untreatable. We are finally seeing progress in pancreatic cancer, something that has been pending for a very long time,” said Sam Godfrey of Cancer Research UK, speaking to the BBC, according to La Brújula 24.
| Response Metric | Outcome Percentage |
|---|---|
| Disease Control Rate | 90.2% |
| Objective Response Rate | 60.7% |
| Complete Response (Undetectable) | 8.2% |
| Survival at 12 Months | 76.6% |
While the results are promising, researchers emphasize that the study is limited by its small sample size and the absence of a direct control group receiving only standard-of-care chemotherapy. Common adverse events observed in the trial included diarrhea, fatigue, and skin rashes, alongside cytopenia associated with the chemotherapy regimen. According to El Debate, only 5% of participants discontinued the drug due to treatment-related side effects.

Michelle Mitchell, chief executive of Cancer Research UK, called the development an advance for a condition that has historically been difficult to treat, though she noted the necessity for further large-scale validation, as reported by La Brújula 24.
“This is the biggest advance we have seen in decades for patients with pancreatic cancer,” Mitchell said. The medical community is now looking toward the international phase III RASolute-303 trial to determine the definitive efficacy of the treatment.
Because researchers have not yet established if the disease will remain in remission long-term, patients are advised to discuss current survival statistics and standard treatment protocols with their clinical team to assess whether participation in experimental trials is appropriate for their specific diagnosis.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.